Anatabine Citrate: Regulatory Strategy Phase 1 underway in EU-Study Completion expected in Third Quarter/2015 Investigational New Drug Application (IND) filed with US FDA -On Clinical Hold, Company plans to respond to FDA in context of overall strategy and ongoing acquisition of preclinical and human clinical data
Intellectual Property-Anatabine Citrate Novel Compound-US Patent 8,557,999 Method of Anatabine synthesis Six pending US and foreign patents pending for “use” of Anatabine, its isomers and derivatives for inflammatory conditions
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.